Development and characterization of a human orthotopic neuroblastoma xenograft

[1]  Bill Bynum,et al.  Lancet , 2015, The Lancet.

[2]  D. Gisselsson,et al.  Neuroblastoma patient-derived orthotopic xenografts retain metastatic patterns and geno- and phenotypes of patient tumours , 2014, International journal of cancer.

[3]  Michael A. Dyer,et al.  Neuroblastoma: developmental biology, cancer genomics and immunotherapy , 2013, Nature Reviews Cancer.

[4]  D. Finkelstein,et al.  Cross-species genomic and epigenomic landscape of retinoblastoma , 2013, Oncotarget.

[5]  Giovanni Parmigiani,et al.  Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma , 2012, Nature Genetics.

[6]  W. Sellers,et al.  Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations , 2012, Molecular Cancer Therapeutics.

[7]  Jinghui Zhang,et al.  Association of age at diagnosis and genetic mutations in patients with neuroblastoma. , 2012, JAMA.

[8]  Kiran C. Bobba,et al.  The genetic basis of early T-cell precursor acute lymphoblastic leukaemia , 2012, Nature.

[9]  K. Matthay,et al.  Paracrine Signaling Through MYCN Enhances Tumor-Vascular Interactions in Neuroblastoma , 2012, Science Translational Medicine.

[10]  Matthew W. Wilson,et al.  A Novel Retinoblastoma Therapy from Genomic and Epigenetic Analyses , 2011, Nature.

[11]  R. Arceci.  The genetic basis of early T–cell precursor acute lymphoblastic leukaemia , 2012 .

[12]  Ninib Baryawno,et al.  Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivo , 2011, International journal of cancer.

[13]  Michael C. Rusch,et al.  CREST maps somatic structural variation in cancer genomes with base-pair resolution , 2011, Nature Methods.

[14]  Sara M. Federico,et al.  Preclinical Models for Neuroblastoma: Establishing a Baseline for Treatment , 2011, PloS one.

[15]  S. Signoretti,et al.  The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma , 2010, Clinical Cancer Research.

[16]  J. Maris.  Recent advances in neuroblastoma. , 2010, The New England journal of medicine.

[17]  Jiang-Ning Zhou,et al.  Roles of autophagy and mTOR signaling in neuronal differentiation of mouse neuroblastoma cells. , 2008, Cellular signalling.

[18]  S. Fulda,et al.  Activation of Akt predicts poor outcome in neuroblastoma. , 2007, Cancer research.

[19]  N. Cheung,et al.  Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Cohn,et al.  The regulation of angiogenesis in neuroblastoma. , 2003, Cancer letters.

[21]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[22]  G. Koehl,et al.  Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor , 2002, Nature Medicine.

[23]  J. Jaboin,et al.  Biologically relevant orthotopic neuroblastoma xenograft models: primary adrenal tumor growth and spontaneous distant metastasis. , 2002, In vivo.

[24]  K K Matthay,et al.  Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid , 1999 .

[25]  A. Wyllie,et al.  Apoptosis is inversely related to necrosis and determines net growth in tumors bearing constitutively expressed myc, ras, and HPV oncogenes. , 1994, The American journal of pathology.